Vinicius Andrade-Oliveira, Mariane T Amano, Matheus Correa-Costa, Angela Castoldi, Raphael J F Felizardo, Danilo C de Almeida, Enio J Bassi, Pedro M Moraes-Vieira, Meire I Hiyane, Andrea C D Rodas, Jean P S Peron, Cristhiane F Aguiar, Marlene A Reis, Willian R Ribeiro, Claudete J Valduga, Rui Curi, Marco Aurelio Ramirez Vinolo, Caroline M Ferreira, Niels Olsen Saraiva Câmara
Short-chain fatty acids (SCFAs) are fermentation end products produced by the intestinal microbiota and have anti-inflammatory and histone deacetylase-inhibiting properties. Recently, a dual relationship between the intestine and kidneys has been unraveled. Therefore, we evaluated the role of SCFA in an AKI model in which the inflammatory process has a detrimental role. We observed that therapy with the three main SCFAs (acetate, propionate, and butyrate) improved renal dysfunction caused by injury. This protection was associated with low levels of local and systemic inflammation, oxidative cellular stress, cell infiltration/activation, and apoptosis...
August 2015: Journal of the American Society of Nephrology: JASN